Vol. 52 | No. 1 | January-June 2024Back

Open Access

The Association of Withdrawing Maintenance Renin-Angiotensin System Inhibitor on All-Cause Mortality and Intensive Care Unit Admission Among Hypertensive Patients Admitted for Mild to Moderate COVID-19 infection:A Meta-analysis of Observational Studies

Arlene Melissa T. Dychiching, Erwin D. Dizon
Jun 2024 DOI 10.69944/pjc.cc03e99186

More Info

Arlene Melissa T. Dychiching, MD | Erwin D. Dizon, MD 

Cardinal Santos Medical Center, San Juan, Metro Manila, Philippines 

Correspondence: 

Email: arlenedychiching@gmail.com; eddcardio@gmail.com 

Declaration of conflicts of interest: None. 

References
  1. Albashir A. Renin-angiotensin-aldosterone system (RAAS) inhibitors and coronavirus disease 2019 (COVID-19). South Med J 2021;114(1):51–56.
  2. Bosso M, Thanaraj T, Abu-Farha M, Alanbaei M, Abubaker J, Al-Mulla F. The two faces of ACE2: the role of ACE2 receptor and its polymorphisms in hypertension and COVID-19. Mol Ther Methods Clin Dev 2020;18:321–327.
  3. Cannata F, Chiarito M, Reimers B, et al. Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother 2020;6(6):412–414.
  4. Chaudhri I, Koraishy F, Bolotova O, et al. Outcomes associated with the use of renin-angiotensin-aldosterone system blockade in hospitalized patients with SARS-CoV-2 infection. Kidney360 2020;1(8):801–809.
  5. Chung M, Karnik S, Saef J, et al. SARS-CoV-2 and ACE2: the biology and clinical data settling the ARB and ACEI controversy. EBioMedicine 2020;58:102907.
  6. De Abajo F, Rodríguez-Miguel A, Rodríguez-Martín S, et al. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study. BMC Med 2021;19(1).
  7. Lam K, Chow K, Vo J, et al. Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis 2020;222(8):1256–1264.
  8. Matsuzawa Y, Kimura K, Ogawa H, Tamura K. Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19. Hypertens Res 2022;45(7):1147–1153.
  9. Naveed H, Elshafeey A, Al-Ali D, et al. The interplay between the immune system, the renin-angiotensin aldosterone system (RAAS), and RAAS inhibitors may modulate the outcome of COVID-19: a systematic review. J Clin Pharmacol 2021;61(8):987–1000.
  10. Spaccarotella C, Mazzitelli M, Migliarino S, et al. Therapy with RAS inhibitors during the COVID-19 pandemic. J Cardiovasc Med 2021;22(5):329-334.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.